You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Blood and immune system conditions
  5. Blood and bone marrow cancers

Rituximab for the treatment of relapsed or refractory stage 3 or 4 follicular non-Hodgkin's lymphoma

  • Technology appraisal guidance
  • Reference number: TA137
  • Published:  27 February 2008
  • Guidance
  • Tools and resources
  • Information for the public
  • Evidence
  • History

Appendix A: provisional matrix of stakeholders

Appendix A: provisional matrix of stakeholders Appendix A: provisional matrix of stakeholders
17 January 2011
(57.5 Kb 16 sec)

Word Viewer may be required.

  Word Viewer may be required.

This page was last updated: 17 January 2011

Back to top